A laboratory on Long Island has found a breakthrough in the fight against pancreatic cancer that can “intercept” its spread.

Scientists have identified a key vulnerability in pancreatic cancer by targeting transcription-replication conflicts—cellular ...

In a recent study, precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS ...

Verastem, Inc.'s priority PDUFA date for avutometinib + defactinib in LGSOC set for June 2025; explore future data updates. Click for my VSTM stock update.

The decision to expand the development plan follows recently reported promising preclinical findings demonstrating that systemic administration of SIL204 significantly inhibits tumor growth in ...

Mutations in the oncogene KRAS are widespread in several human cancers, including pancreatic ductal adenocarcinomas (92%), colorectal carcinomas (49%) and lung adenocarcinomas (35%). These mutations ...

Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had ...

Verastem (VSTM) stock in focus as Jefferies initiates a Buy rating with a $15 target, citing a potential FDA approval for its ovarian cancer drug combo. Read more here.

Researchers have identified a new molecular target for treating pancreatic cancer. Scientists focused on transcription-replication conflicts (TRCs), which occur when the mechanisms responsible for ...

Pancreatic ductal adenocarcinom a (PDAC), frequently detected at advanced stages, has a 5-year survival rate of 12%. Metastases are common, including hepatic metastasis, which is particularly lethal ...